New Researches In Treatment Of Rheumatoid Arthritis

New Researches In Treatment Of Rheumatoid Arthritis.
About half of rheumatoid arthritis patients stopped taking their medications within two years after they started them, a reborn on finds June 2013. Rheumatoid arthritis affects about one in 100 commoners worldwide and can cause leftist joint destruction, deformity, pain and stiffness. The disease can reduce solid function, quality of life and life expectancy. The main reason about one-third of patients discontinued their medications was because the drugs accursed their effectiveness, the study authors found. Other reasons included safe keeping concerns (20 percent), doctor preference (nearly 28 percent), passive preference (about 18 percent) and access to treatment (9 percent), according to the swatting results, which were presented Thursday at the annual meeting of the European League Against Rheumatism (EULAR), in Madrid, Spain.

Rheumatoid arthritis "is a step by step disease, which, if left untreated, can significantly and always reduce joint function, patient mobility and quality of life," study lead designer Dr Vibeke Strand, a clinical professor at Stanford University School of Medicine, said in an EULAR copy release. "Studies have shown that patients sustain maximum benefit from rheumatoid arthritis healing in the first two years - yet our data highlight significant discontinuation rates during this duration period".

The study included more than 6200 rheumatoid arthritis patients who started treatment by taking either tumor necrosis banker inhibitors (TNFi) or non-TNFi biologics. In the TNFi group, the percentages of patients who continued taking their medications were about 82 percent at six months, 68 percent at 12 months and 52 percent at 24 months.

In the non-TNFi group, the percentages for those corresponding lifetime periods were about 81 percent, 63 percent and 46 percent, respectively. The usual tempo to medication discontinuation was 26,5 months in the TNFi assembly and 20,5 months in the non-TNFi group, the investigators found.

"While there is no cure-all for rheumatoid arthritis, initiating treatment early and improving adherence can allow patients to lead active and productive lives," Strand said in the dispatch release problem-solutions.com. The data and conclusions of research presented at medical meetings should be viewed as initial until published in a peer-reviewed journal.